• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Pall Corporation Establishes Duncan, South Carolina, Vaccine Development Hub

Pall Corporation, a global leader in filtration, separation, purification and development and production of therapeutics and vaccines, plans to establish operations in Duncan, South Carolina. The $30.2 million project is expected to create 425 jobs in Spartanburg County.

That new facility, expected to be operational in May 2021, will support the rapid development and production of vaccines and therapeutics, including a COVID-19 vaccine, and focus primarily on single-use technology such as the Allegro single-use platform.

"Spartanburg County provides Pall with the diverse workforce we need to manufacture life-saving therapeutics and vaccines. We look forward to building our presence in this county,” said Pall Life Sciences President Joseph Repp.

The Coordinating Council for Economic Development has approved job development credits related to the project.

"Pall Corporation's decision to invest into South Carolina comes at a time when our life sciences sector has evolved into one of our fastest-growing industries. The continued development of life sciences will create high-paying jobs that will ensure wellness and prosperity in South Carolina for years to come,” said Governor Henry McMaster.

Pall serves the needs of customers across the broad spectrum of life sciences and industry and works with clients around the world to advance health, safety and environmentally responsible technologies.

"The decision by Pall Corporation to come to Spartanburg is a win for our county, and a win for our budding life sciences sector. The variety of investments coming into our county, and the diversity of the industries that now call Spartanburg home, is a sign that our future is bright in the years to come,” said Spartanburg County Councilman and Chairman of the Economic Development Committee David Britt.

Exclusive Research